Clearside Biomedical, Inc.

CLSDQ OTC CIK: 0001539029

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 900 NORTH POINT PARKWAY, ALPHARETTA, GA, 30005
Mailing Address 900 NORTH POINT PARKWAY, ALPHARETTA, GA, 30005
Phone 678-270-3631
Fiscal Year End 1231
EIN 452437375

Financial Overview

FY2024

$34.02M
Total Assets
$48.26M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events December 29, 2025 View on SEC
8-K Current report of material events December 8, 2025 View on SEC
8-K Current report of material events November 25, 2025 View on SEC
10-Q Quarterly financial report November 14, 2025 View on SEC
8-K Current report of material events October 7, 2025 View on SEC
8-K Current report of material events September 11, 2025 View on SEC
8-K Current report of material events September 11, 2025 View on SEC
8-K Current report of material events September 8, 2025 View on SEC
8-K Current report of material events September 3, 2025 View on SEC
8-K Current report of material events August 14, 2025 View on SEC

Material Events

8-K Bankruptcy December 29, 2025
High Impact
  • Clearside Biomedical, Inc. has filed for Chapter 11 bankruptcy due to serious financial trouble.
  • The company is reorganizing under court supervision and plans to sell off all or most of its assets.
View Analysis
8-K Bankruptcy December 8, 2025
High Impact
  • Clearside Biomedical, Inc. has filed for Chapter 11 bankruptcy protection (Case No. 25-12109).
  • The company's stock was delisted from the Nasdaq stock exchange due to the bankruptcy filing.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.